- Approval Id
- 63379dab1260f5db
- Drug Name
- ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V
- Product Name
- ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V
- Approval Number
- SIN16818P
- Approval Date
- 2023-07-04
- Registrant
- SANTEN PHARMACEUTICAL ASIA PTE. LTD.
- Licence Holder
- SANTEN PHARMACEUTICAL ASIA PTE. LTD.
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- SOLUTION, STERILE
- Dosage
- **2\. DOSAGE AND ADMINISTRATION**
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN should not exceed once daily.
ROCKLATAN may be used concomitantly with other topical ophthalmic drug products to lower IOP.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Due to netarsudil’s vasodilating properties, other eye drops should be administered before latanoprost + netarsudil. Eye ointments should be administered last.
- Route Of Administration
- OPHTHALMIC
- Indication Info
- **1\. INDICATIONS AND USAGE**
ROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin F2α analogue or Rho kinase inhibitor provides insufficient IOP reduction.
- Contraindications
- **4\. CONTRAINDICATIONS**
Hypersensitivity to the active substance(s) or to any of the excipients.
- Atc Code
- S01EE51
- Atc Item Name
- latanoprost and netarsudil
- Pharma Manufacturer Name
- SANTEN PHARMACEUTICAL ASIA PTE. LTD.
- Company Detail Path
- /organization/santen-pharmaceutical-asia-pte-ltd
